Dynamic trafficking patterns of IL-17-producing γδ T cells are linked to the recurrence of skin inflammation in psoriasis-like dermatitis

Na Liu,a,b,c,1 Hui Qin,a,b,1 Yihua Cai,b,1 Xia Li,a Lanqian Xu,a, Qiannan Xu,a Feng Xue,a Lihong Chen,a Chuanlin Ding,b Xiaoling Hu,b David Tieri,d Eric C. Rouchka,d Jun Yan,b* and Jie Zheng*a*

aDepartment of Dermatology, Ruijin Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200025, PR China
bDivision of Immunotherapy, Department of Surgery, Immuno-Oncology Program, James Graham Brown Cancer Center, University of Louisville, Louisville, KY 40202, USA
cDepartment of Dermatology, Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai 200443, PR China
dDepartment of Biochemistry and Molecular Genetics, University of Louisville, Louisville, KY 40202, USA

Summary

Background Psoriasis recurrence is a clinically challenging issue. However, the underlying mechanisms haven’t been fully understood.

Methods RNAseq analysis from affected skin of psoriatic patients treated with topical glucocorticoid (GC) with different outcomes was performed. In addition, imiquimod (IMQ)-induced mouse psoriasis-like model was used to mimic GC treatment in human psoriasis patients. Skin tissues and draining and distant lymph nodes (LNs) were harvested for flow cytometry and histology analyses.

Findings RNAseq analysis revealed that chemokine and chemokine receptor gene expression was decreased in post-treated skin compared to pre-treated samples but was subsequently increased in the recurred skin. In IMQ-induced mouse psoriasis-like model, we found that γδT17 cells were decreased in the skin upon topical GC treatment but surprisingly increased in the draining and distant LNs. This redistribution pattern lasted even two weeks post GC withdrawal. Upon IMQ re-challenge on the same site, mice previously treated with GC developed more severe skin inflammation. There were γδT17 cells migrated from LNs to the skin. This dynamic trafficking was dependent on CCR6 as this phenomenon was completely abrogated in CCR6-deficient mice. In addition, inhibition of lymphocyte egress prevented this heightened skin inflammation induced by IMQ rechallenge.

Interpretation Redistribution of pathogenic γδT17 cells may be vital to prevent disease recurrence and this model of psoriasis-like dermatitis.

Funding This work was supported by National Natural Science Foundation of China 81830095/H1103, 81761128008/H10 (J.Z.) and the NIH R01AI28818 and the National Psoriasis Foundation (J.Y.).

Copyright © 2022 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

Keywords: Psoriasis; γδ T cells; Migration; IL-17; Skin inflammation; CCR6

Introduction

Psoriasis is an autoimmune chronic inflammatory skin disease affecting approximately 2% of population worldwide.1 The common challenge for psoriasis treatment including conventional topical glucocorticoid (GC) treatment and many newly approved biologics is eventually disease recurrence in weeks or months interval after drug withdrawal.2–5 Intriguingly, when disease recurs, the appearance of new lesions is often in the place of previous ones, suggesting immune memory involvement.6 It was thought that psoriasis-specific Th17/Tc17 cells and tissue resident memory T cells (TRM) play critical roles in this process.7–10 In addition to adaptive T cells, innate γδ T cells are also thought to be involved in psoriasis immunopathogenesis.11,12 Previous studies have showed that dermal γδ T cells are the major
Research in context

Evidence before this study

Psoriasis is a skin autoinflammatory disease with no cure. One of the most challenging aspects of treating psoriasis is the tendency of psoriatic lesions to recur after treatment is discontinued. Previous studies have implicated that psoriasis-specific Th17/Tc17 cells and tissue resident memory T cells (T\textsubscript{RM}) play critical roles in disease recurrence. In addition, innate γδ T cells are also thought to be involved in psoriasis pathogenesis. However, how these cells involve in disease recurrence and the underlying mechanisms remain largely unexplored.

Added value of this study

Our findings suggest that trafficking pattern changes of pathogenic γδT17 cells play a critical role in skin inflammation recurrence in psoriasis-like dermatitis. γδT17 cell dynamic trafficking between skin and draining and distant lymph nodes is dependent of CCR6. Through unbiased RNA sequencing (RNA-Seq) analyses provide insights into understanding psoriasis pathogenesis. Interestingly, innate γδ T cells are also shown to bear “memory” phenotype. Despite these studies, how these cells involve in disease recurrence and the underlying mechanism remain elusive.

Implications of all the available evidence

Our study suggests inhibition of pathogenic γδT17 cell redistribution as an effective treatment to prevent disease recurrence in patients with psoriasis and in psoriasis-like dermatitis.

Methods

Human subjects

Twenty-one patients (age, 27-69 years old) with psoriasis vulgaris were recruited. Peripheral blood (PB) and skin biopsies of patients were taken. Patient demographics and clinical characteristics were summarized in the Supplemental Table 1. Detailed psoriasis area and severity index (PASI) scores from each patient and information related to previous treatments in these patients were summarized in Supplemental Table 2. None of the patients had been treated with topical drugs other than emollients at least 2 weeks prior to the study entry. The study was approved by the Shanghai Jiaotong University Ruijin Hospital Ethics Committee (IRB#1.1/2014-10-13). All the participants gave their written informed consent.

Patient treatment

All patients received the topical treatment of Halometasone cream (GC, Hong Kong Bright Future Pharmaceuticals) once daily for 2 weeks. Halometasone was withdrawn for 4 weeks and then assessed the severities of psoriatic lesions by PASI. One patient was excluded due to loss of follow-up. All other patients completed the schedule. PB and approximate 8 mm skin biopsy were taken at the typical lesion areas before treatment, after treatment and 4 weeks after GC withdrawal. A total of 11 patients experienced episodes of effective treatment then recurrence. Half of the biopsy tissues was used for histology and immunofluorescent staining and the other half of tissue was used for RNA extraction.

cellular source of IL-17 in the mouse skin and play a critical role in imiquimod (IMQ)-induced psoriasis-like skin inflammation and human psoriatic pathogenesis. Interestingly, innate γδ T cells are also shown to bear “memory” phenotype. Despite these studies, how these cells involve in disease recurrence and the underlying mechanism remain elusive.

A previous study using lesional skin but now normal-appearing skin upon TNF-α antagonist antibody (Ab) treatment has revealed that a set of inflammation-related genes remain elevated in treated lesions. In addition, genes related to lymphatic vessels and skin structural cell types are also altered. These correlative analyses provide insights into understanding psoriasis recurrence. To further dissect the mechanism underlying disease recurrence, we recruited a cohort of psoriatic patients who received topical GC treatment. Lesional skin before GC treatment was biopsied from all patients (pre-treated). Patients who had effective treatment also had skin biopsy (post-treated). A fraction of patients had recurrence and skin biopsy was again performed (recurrant). Through unbiased RNA sequencing (RNA-Seq) analysis from these skin tissues, we found that chemokine/chemokine receptor gene expression such as CCL20 was decreased in post-treated skin compared to that in pre-treated lesional skin but subsequently increased in the recurred skin. These findings led us to hypothesize that differential trafficking patterns of pathogenic IL-17-producing cells in psoriasis may play a critical role in disease recurrence. IMQ-induced psoriasis-like mouse model has been extensively studied and this model recapitulates some markers of human psoriasis such as skin histopathology. We modified this model to help dissect potential cellular etiology underlying psoriasis recurrence. We found that innate γδT cells (γδT17) were initially increased in dermis upon disease induction by IMQ but surprisingly migrated into draining and distant lymph nodes (LNs) after effective GC treatment. γδT17 cells persisted for a long time and then quickly trafficked back to the inflamed skin to induce the heightened skin inflammation, mimicking human psoriasis recurrence. This process was dependent on CCR6, and inhibition of lymphocyte egress abrogated the heightened skin inflammation. Collectively, these data suggest that the trafficking pattern changes of pathogenic γδT17 cells may hold the key in regulating disease recurrence in this model of psoriasis-like dermatitis.
The biopsy tissues from additional three patients were used for flow cytometry analysis.

**Mice**

Wildtype (WT) C57BL/6 mice (RRID:IMSR_JAX:000664), Tcrd+/- (RRID:IMSR_JAX:002120), Ccr6-/- (RRID:IMSR_JAX:007593) and Ccr2-/- mice (RRID:IMSR_JAX:004999) on C57BL/6 background were purchased from Jackson Laboratory and bred at the University of Louisville animal facility. All animals were housed and treated in accordance with institutional guidelines and approved by the Institutional Animal Care and Use Committee (IACUC) at the University of Louisville.

**Mouse treatments**

WT, TCRd+/-, Ccr6-/-, and Ccr2-/- mice between 6 and 8 weeks of age were divided into Vas control group and GC treatment group. Mice were treated daily for 5 days on each ear with 10mg of 5% imiquimod cream (3M Health Care Limited) to induce psoriasis-like inflammation. From Day 6, GC group mice were treated with 10mg GC (Sigma) and then filtered through 40 μm (mouse) or 100 μm (human) cell strainers. Human PBMCs were separated by density gradient centrifugation using Ficoll paque premium (GE healthcare), according to the manufacturer’s instruction. Cervical LNs and inguinal LNs from mice were also harvested to prepare single-cell suspensions.

**Flow cytometry analysis and intracellular staining**

Fluorochrome-labeled mAbs including anti-mouse CD3 (17A2, RRID: AB_1595492), γδTCR (GL3, RRID: AB_1595492), Vγ4 (UC3-10A6, RRID: AB_10569353), Vδ4 (GL2, RRID: AB_1877234), CD45 (30-F11, RRID: AB_312973), CD11b (M1/70, RRID: AB_312791), Gr-1 (RB6-8C5, RRID: AB_313377), and IL-17A (TC11-18H10.1, RRID: AB_312973), CD11b (M1/70, RRID: AB_312791), Gr-1 (RB6-8C5, RRID: AB_313377), and IL-17A (TC11-18H10.1, RRID: AB_312973), and IL-17R (DIH9, RRID: AB_2687367) were purchased from Biolegend. Anti-human γδTCR (REA591, Cat # 130-113-508) was purchased from Miltenyi Biotec and anti-human CD3 (UCHT1, Cat # 550795S) was purchased from BD bioscience. For intracellular IL-17 staining, mouse skin cells or LN cells were treated with GolgiPlug (Biolegend) at 37°C for 4 h. Cells were first blocked with anti-CD16/32 and then stained with different cell surface Abs at 4°C for further processing. In brief, tissue samples were placed in 2 ml tubes (axygen, City, CA) and stored at -80°C overnight for IL-17A. The relevant isotype control mAbs were also used. Samples were harvested with BD FACS Canto and analyzed with FlowJo software (TreeStar).

**RNA isolation**

Skin biopsy tissues were placed in Trizol (Ambion, Foster City, CA) and stored at -80°C for further processing. In brief, tissue samples were placed in 2 ml tubes (oxygen, Corning) along with three stainless steel balls and run through tissue lyser (Jingxin, Shanghai, China) 60HZ with 60s for 3-6 times until the tissues were completely grinded. RNA was extracted using the Eastep® Super Total RNA Extraction Kit (Promega, Shanghai, China) based on manufacturer instructions.

**Real time quantitative polymerase chain reaction (qRT-PCR)**

Isolated RNA was reverse transcribed into cDNA with a Reverse Transcription Kit (Takara, Shiga Japan). qRT-PCR was performed using SYBR Green Master (Roche, Basel, Switzerland) according to the manufacturer’s instructions and gene-specific primers were summarized in the Supplemental Table 3. qRT-PCR was done on an Applied Biosystems 7500. We normalized gene expression amount to GAPDH (human) or β-MG.
(mouse) housekeeping genes and represented data as fold changes by the ΔΔCt method.

RNA-Seq
Total RNA was extracted and library was constructed and sequenced with sequencing platform BGISEQ-500 (BGI). The sample sequences were directly aligned to the Homo sapiens hg38 reference genome assembly using tophat2 (version 2.0.13), generating alignment files. The number of reads was between 37 to 52 million. The alignment rate ranged from 88-93% across the samples from the left read, and 76-88% for the right read, resulting in a concordant mapping rate of 72-83%. Quality control of the raw sequence data was performed using FastQC (version 0.10.1). For the first read, the interquartile range remained above 30 (99.9% base call accuracy); across the reads. Differential expression analysis was performed using the Tuxedo Suite program cuffdiff2 (version 2.2.1). A q-value cutoff ≤ 0.05 with |FC| ≥ 1 was used to determine differential expression. RNA-Seq data have been deposited into NCBI GEO with the accession number (GSE114729).

Skin histology
Fresh human and mouse skin samples were fixed in 4% paraformaldehyde solution for 24h, dehydrated, and embedded in paraffin. Tissue sections (∼10μm in thickness) were used for various staining. For histopathology, human and mice sections were stained with hematoxylin and eosin (H&E). The ear skin from WT and Tcrd+/− mice was dissected and frozen in optimal cutting temperature (OCT) compound. Sections (10μm thick) were cut with a cryostat. The slides were stained with hematoxylin and eosin for morphology and cellular infiltration. Images were acquired at ×200 magnification using Aperio ScanScope digital scanners.

Immunofluorescence staining
For immunofluorescence, the ear skin from WT and Tcrd−/− mice was dissected and frozen in optimal cutting temperature (OCT) compound. Sections (10μm thick) were cut with a cryostat. After fixation with cold acetone for 30 min, slides were blocked with 20% FBS in PBS for 60 min at room temperature, and then stained with anti-mouse Gr-1 (RB6-8C5, 1:100, Biolegend) in 20% FBS at 4 °C overnight. Nuclei were visualized by DAPI (1 μg/ml, Invitrogen, USA) staining for 10 min. Images were acquired by Nikon confocal microscope system.

Statistics
Differences between two sets of data were evaluated by 2-tailed Student’s t-test. For more than two groups, we used nonparametric multiple testing methods with human data while one-way or two-way ANOVA was used for mouse data analysis. Data represent mean and error or mean ± SEM as indicated. P ≤ 0.05 was considered statistically significant. All statistics were done using GraphPad Prism (GraphPad Software).

Role of funders
The Funders had no roles in study design, data collection, data analyses, interpretation or writing of report.

Results
Skin tissues from psoriasis patients show fluctuated chemokine levels that are correlated with different disease episodes
To investigate the possible etiology underlying psoriasis recurrence, GC was topically applied on the lesional skin for 2 weeks and then withdrawn. A total 11 patients experienced episodes of effective treatment and then recurrence. Skin tissues (pre-treated, post-treated, and recurrent) from these patients were obtained and subjected to RNA-Seq analysis. Upon effective treatment with GC, many genes and pathways related to psoriasis pathogenesis including TCR pathway, keratinocyte pathway, and positive regulation of innate immune response were downregulated (Figure S1a, S1c). In contrast, when disease recurred, these genes and pathways were upregulated or enriched (Figure S1b, S1d). In addition, the mRNA expression levels of IL-17 and IL-23 were also decreased post GC treatment while upregulated after disease relapse (Figure S1e). Notably, lymphocyte chemotaxis pathway including chemokine/chemokine receptor genes was among this list (Figure 1a), including CCL20, CCL5, and CXCL10. These gene expression levels in the skin from different disease stages were also validated by qRT-PCR analysis (Figure 1b). CCL20 is a ligand for CCR6 which is expressed on all IL-17-producing T cells (T17), supporting critical roles of IL-17 played in psoriasis pathogenesis, treatment response, and disease recurrence. Since a previous study reported that proinflammatory human skin-homing Vγ9Vδ2 T cells are associated with psoriasis treatment response,19 we thus examined CD3⁺ T cells and innate γδ T cells in the skin and peripheral blood (PB) during GC treatment. Upon effective GC treatment, skin infiltrating CD3⁺ T cells were decreased and so were dermal γδ T cells (Figure 1c and 1e). When disease recurred, CD3⁺ T cells as well as γδ T cells were increased in the lesional skin. In contrast, γδ T cells in the PB experienced an opposite wave as compared to skin-infiltrating γδ T cells. Circulating γδ T cells were increased upon effective GC treatment while decreased when disease recurred (Figure 1d, 1f and 1g) although total CD3⁺ T cells in the PB did not follow this trend. This was revealed by both fold changes and absolute
Figure 1. Differential chemokine/chemokine receptor gene expression profiles by RNAseq analysis and γδ T cells in human psoriasis patients. (a) Heatmaps show the differentially expressed chemokines/chemokine receptors genes in the pre- versus post-treated skins and post-treatment versus recurrent skins. (b) The mRNA expression levels of CCL20, CCL5, CCL2, and CXCL10 assessed by real-time PCR analysis in the pre-, post-, and recurrent skins (n=21). *P<0.05, **P<0.01 (nonparametric multiple test). (c) Skin biopsies from pre-, post- and recurrent patients were stained with CD3, pan γδ TCR, and viability dye. Cells were gated on viable (upper) or CD3+ cells (lower). Representative flow plots are shown. (d) PB sample obtained from the same patient in panel c was stained with CD3 and pan γδ TCR. Cells were gated on total PBMC or CD3+ cells. Representative flow plots are shown. (e) Summarized percentages of dermal γδ T cells in skin tissues from three pre-, post-treatment, and recurrent psoriatic patients. (f) Fold changes of PB γδ T cells from patients before and after treatment (n=21) and post-treatment and recurrent (n=20) are shown. *P<0.05 (paired Student’s t test). (g) Absolute numbers of γδ T cells in 1ml PB from patients before and after treatment (n=21) and post-treatment and recurrent (n=20) are shown. *P<0.05 (paired Student’s t test). Data in the bar figures are represented as means±SEM.
numbers (Figure 1f and 1g). These findings suggest that trafficking changes of T cells, particularly innate γδ T cells may be associated with disease resolution and recurrence in psoriasis.

**IMQ-induced psoriasis-like skin inflammation is ameliorated upon GC treatment with decreased γδT17 cells in the skin but increased in the distant LNs**

To delineate the mechanisms underlying psoriasis recurrence, we used a well-established IMQ-induced psoriasis-like dermatitis model to mimic human psoriasis patients. Consistent with previous reports, ear thickness was significantly lower in TCR δ-deficient (Tcrd−/−) mice (Figure 2b right), suggesting critical role of γδ T cells in this model system. This was also confirmed by skin histology analysis (Figure 2c). We then extensively phenotyped T cells in the skin and draining and distant LNs from these mice by flow cytometry. The gating strategy for the skin tissues (Figure S2a) and LNs (Figure S2b) is shown in Figure S2. GC treatment drastically reduced CD3+ T cells in the skin (Figure S2a), similar to psoriatic patients. Dermal γδ T cells, particularly Vγ4Vδ4 T cells were significantly decreased in GC treated mice (Figure S2a). In contrast, IL-17 production from these cells was significantly increased in GC-treated mice compared to these in Vas control mice (Figure 2g). In addition, the absolute number of IL-17-producing γδ T cells and Vγ4 T cells was also significantly increased (Figure 2g). In contrast, CD3+γδ T cells produced minimal IL-17 and no difference was noticed in the skin draining and distant LNs although Th17 cells were lower in the skin in GC-treated mice (Figure S3d). Interestingly, IL-1R expression levels on dermal γδ T cells, Vγ4 T cells, and Vγ4Vδ4 T cells were significantly increased in GC-treated mice (Figure S3e). Upregulation of IL-1R is found to be associated with memory Vγ4 T17 cells in skin inflammation.16 These data suggest that decreased γδT17 cells in the GC-treated inflamed skin may migrate into skin draining and distant LNs with memory phenotype.

**γδT17 cells persist in the draining and distant LNs after GC treatment withdrawal**

To mimic human psoriasis patient’s treatment schedule, these mice were rested for 2 weeks after GC treatment. Ear thickness in Vas control mice was gradually decreased over time (Figure 2a). This was also confirmed by skin histology (Figure 2a). However, skin-infiltrating neutrophils were found surprisingly to be more in the GC-treated mice compared to Vas control mice although no difference was observed in Tcrd−/− mice (Figure 3a). The frequency and absolute number of total dermal γδT17 cells and IL-17-producing Vγ4 and Vγ4Vδ4 T cells remained significantly lower in GC-treated mice (Figure 3d) compared to those in Vas-treated control mice. In contrast, IL-17 production from these cells in draining and distant LNs of GC-treated mice, both frequency and absolute number, was still significantly higher than those in Vas control mice (Figure 3e, f). It appears that γδT17 cells remain accumulated in the draining and distant LNs after GC treatment withdrawal for 2 weeks.

**Rechallenge of previously GC-treated mice on the same site drives γδT17 cell trafficking from LNs to the dermis resulting in a heightened inflammation**

We next re-challenged these mice with IMQ on the same ear to mimic human psoriasis recurrence. After three days of IMQ application, the changes of ear thickness from previously GC-treated mice were significantly higher than Vas control mice (Figure 4a left). However, this phenomenon was reversed in Tcrd−/− mice (Figure 4a middle). Similarly, fold changes of epidermal thickness also showed significantly increase in these mice although no difference was seen in Tcrd−/− mice (Figure 4a right). This was also confirmed with skin histology analysis (Figure 4b). More neutrophils were accumulated in the previously GC-treated mouse skin as revealed by both immunofluorescent staining and flow cytometry (Figure 4c). This was opposite in Tcrd−/−...
Figure 2. GC treatment reduces skin inflammation and drives γδT17 cells from skin to the draining and distant LNs. (a) Schema for mouse model establishment. (b) Mouse ear thickness was measured daily from Day 1 to Day 21. (Left) Ear thickness from WT/IMQ/Vas and WT/IMQ/GC groups (n=24 in each group). Data are the combination of two experiments and represent as mean and error. ****P<0.0001 (unpaired Student’s t test). (Right) Ear thickness from WT/IMQ/Vas, Tcrd−/−/IMQ/Vas, and Tcrd−/−/IMQ/GC groups (n=5 in each group). ***P<0.001 (one-way ANOVA) (c) Representative HE stained skin sections of WT and Tcrd−/− mice on Day 21, scale bar=50 m. (d) (Left) Representative immunofluorescence stained skin sections of WT mice treated with GC or Vas on Day 21 (Gr-1, red; DAPI, blue). scale bar=50 m. (Right) Summarized neutrophil percentages assessed by flow cytometry (WT n=5, Tcrd−/− n=3) are shown. Cells were gated on CD45+CD11b+ cells. ***P<0.001 (one-way ANOVA). (e-g) IL-17 production by CD3, γδT, Vγ4, and Vγ4Vδ4 T cells from skin (e), cervical LNs (f), and inguinal LNs (g) (n=5 in each group) on day 21. Representative flow plots and absolute number are shown. Cells were gated on CD3, γδTCR, Vγ4, Vγ4Vδ4 T cells, respectively. Data are representative of at least two independent experiments with similar results. ****P<0.0001, ***P<0.001, **P<0.01, *P<0.05 (unpaired Student’s t test). Data in the bar figures are represented as means±SEM.
Figure 3. GC treatment withdrawal maintains the distribution patterns of γδT17 cells in the skin and draining and distant LNs. (a) Ear thickness of WT mice from Day 21 to Day 35. Data are the combination of two experiments (n=14) and represent as mean and error. ***P<0.001 (unpaired Student’s t test). (b) Representative HE stained skin sections of WT and Tcrd−/− mice on Day 35, scale bar=50 μm. (c) Neutrophil infiltration. Representative flow plots and summarized percentages are shown. Cells were gated on CD45+CD11b+ cells (WT n=9, Tcrd−/− n=3). Data are representative of at least two independent experiments with similar results. **P<0.01 (one-way ANOVA). (d-f) IL-17 production by CD3+, dermal or LNs γδ T, Vγ4 T, Vγ4Vδ4 T cells from skin (d), cervical LNs (e) or inguinal LNs (f) on day 35. Flow plots were gated on CD3+, γδ TCR, Vγ4, Vγ4Vδ4 T cells, respectively. Representative flow plots and summarized percentage and absolute number are shown (n=4 in WT/IMQ/GC group, n=5 in WT/IMQ/Vas group, n=3 in each group of Tcrd−/− mice). Data are representative of at least two independent experiments with similar results. ****P<0.0001, ***P<0.001, **P<0.01 *P<0.05 (unpaired Student’s t test). Data in the bar figures are represented as means±SEM.
Figure 4. Rechallenge of IMQ in mice previously treated with GC induces more severe skin inflammation. (a) (Left and middle) Changes of ear thickness of WT mice and Tcrd−/− mice from Day 36 to Day 42 (ear thickness on day 35 was used as the base level). Data are combination of two experiments (n=8 in each group) and represent as mean and error. ****P<0.0001, ***P<0.001 (unpaired Student’s t test). (Right) Fold increase of ear thickness of WT mice (n=5) or Tcrd−/− mice (n=2-3). Data are the representative of at least two independent experiments with similar results. **P<0.01 (one-way ANOVA).

(b) Representative skin HE stained sections of WT or Tcrd−/− mice previously treated with or without GC on Day 42. Scale bar=50 μm.

(c) (Left) Representative neutrophil immunofluorescence stained skin sections of WT mice on Day 42, scale bar=50 μm. (Right) Summarized percent of neutrophils in the skin. Neutrophils were gated on CD45+CD11b+ cells. The results are the combination of two experiments (n=10 in each WT mice group. n=6 in each Tcrd−/− group). ***P<0.001, *P<0.05 (one-way ANOVA).

(d-f) IL-17 production by dermal or LNs CD3, γδ, Vγ4, Vγ4Vδ4 T cells from skin (d), cervical LNs (e) or inguinal LNs (f) (n=5) on day 42. Flow plots were gated on γδ TCR, Vγ4, Vγ4Vδ4 T cells, respectively. Representative flow plots and summarized percentage and absolute number are shown (n=5 at each WT mice). Data are representative of at least two independent experiments with similar results. (unpaired Student’s t test). Data in the bar figures are represented as means±SEM.
mice. IL-17 production from CD3+ T cells and γδ T cells in the skin was similar between GC-treated and Vas control mice (Figure 4d). This was for both frequency and absolute number. No difference was noticed for γδT17 cells in the skin draining and distant LNs between these two groups (Figure 4e, 4f). This was in sharp contrast to the significant increase of these cells before IMQ re-challenge (Figure 3e and 3f). These data suggest that γδT17 cells accumulated in the skin draining and distant LNs from previously GC-treated mice may migrate back to the skin leading to the increased severity of skin inflammation.

To further determine the critical role of γδ T cell trafficking pattern in mediating the heightened skin inflammation in previously GC treated mice, we sorted γδ T cells from skin draining LNs of previously GC-treated or Vas control mice on day 35. These cells were adoptively transferred into naïve mice and recipient mice were then applied IMQ on the ears (Figure S4a). As shown in Figure S4b, mice received γδ T cells from GC-treated mice had significantly increased epidermal thickness than those from control mice starting at day 4 post transfer. In addition, the percentages of IL-17-producing dermal CD3+, Vγ4 T cells, and Vγ4Vδ4 T cells were all increased in these mice (Figure S4c) while no difference was noticed in the draining and distant LNs (Figure S4d). These data suggest the causative role of γδ T cells in inducing this heightened skin inflammation. To examine the specificity of IMQ rechallenge in previously GC-treated or Vas control mice, the second IMQ application was done on the different ear from primary IMQ treatment (Figure S4e). Mice challenged with IMQ on the same ear were used as control. Consistent with previous results, GC-treated mice rechallenged with IMQ on the same ear showed the increased epidermal thickness compared to Vas control mice (Figure S4f). However, GC-treated mice received the second IMQ application on the opposite ear showed significantly decreased epidermal thickness compared to Vas control mice (Figure S4f). In addition, the overall percentages of IL-17 production from CD3, total γδ, Vγ4, and Vγ4Vδ4 T cells in the skin from these mice were substantially lower than those from mice received the second IMQ on the same ears (Figure S4g). In contrast, IL-17-producing Vγ4 and Vγ4Vδ4 T cells were still higher in the draining LNs of these mice received IMQ rechallenge on the opposite ears (Figure S4h). These data indicate that the heightened skin inflammation upon GC treatment is induced in the same lesional skin, reminiscent of human psoriasis recurrence.

Inhibition of lymphocyte egress abrogates γδT17 cell trafficking and subsequent skin inflammation

Having demonstrated critical roles of γδT17 cell trafficking in skin inflammation, we thought inhibition of this migration may provide an effective approach to control inflammation. A small molecule FTY720 is the FDA approved drug that inhibits lymphocyte egress from lymphoid tissues via downregulating sphingosine-1 phosphate receptor (S1PR) for multiple sclerosis treatment. To foster potential clinical translation in human psoriasis patients, we used FTY720 on day 35 before IMQ re-challenge. Administration of FTY720 completely abrogated enhanced ear thickness in previously GC-treated mice upon IMQ re-challenge (Figure 6a) and the changes of ear thickness were significantly lower in GC-treated mice compared to Vas control mice. Similarly, increased neutrophil accumulation was abrogated (Figure 6a). In addition, IL-17 production from CD3+ T cells and total γδT cells in the skin was significantly decreased in mice treated with FTY720 (Figure 6b). This was not only for GC-treated mice but also for Vas control mice. FTY720 administration before IMQ re-challenge led to an even more marked accumulation of γδT17 and Vγ4Tγ4 in the skin

CCR6 is essential for γδT17 cell dynamic trafficking between LNs and dermis

Previous studies have shown that CCR2 and CCR6 play critical roles in γδT17 cell migration during skin inflammation. We thus used home-bred WT, Ccr2−/−, and Ccr6−/− mice to examine whether γδT17 cell trafficking is responsible for the observed phenotype. In addition, three strains of mice from the same facility were used to eliminate the potential impact of skin microbiota. Although upon GC treatment, all strains of mice showed decreased ear thickness, significant differences were recorded between WT and Ccr6−/− mice (Figure 5a) but Ccr2−/− mice did similarly as WT mice (Figure 5b). Neutrophil accumulation in GC-treated WT and Ccr2−/− mice were also significantly lower than that in Vas control mice but there was no difference in Ccr6−/− mice (Figure 5c). In the skin, IL-17 production from total CD3+ T cells, γδT cells, Vγ4 T cells, and Vγ4Vδ4 T cells was all significantly decreased upon GC treatment (Figure 5d). However, the increased IL-17 production from these cells in the draining and distant LNs was completely abrogated in Ccr6−/− mice (Figure 5e). In fact, GC-treated mice received the second IMQ from total CD3+ T cells, γδT cells, Vγ4 T cells, and Vγ4Vδ4 T cells was all significantly lower than in Vas control mice. FTY720 administration in these pretreated mice, both WT and Ccr2−/− mice received GC treatment previously showed similar increased changes of ear thickness (Figure 5f and data not shown). However, this phenotype was abrogated in Ccr6−/− mice and Ccr6−/− mice previously treated with GC had significantly decreased epidermal thickness as compared to Vas treated control Ccr6−/− mice (Figure 5f). Histology also revealed similar phenotype (Figure 5g). Taken together, these data suggest that CCR6 deficiency abrogates γδT17 trafficking from affected skin to the draining and distant LNs and vice versa.
draining LNs (Figure 6c left) while these cells were drastically decreased in the distant LNs (Figure 6c right). The substantial decrease in these cells was also observed in Vas control mice. These data suggest that following expansion in the draining LNs, inhibition of γδT17 cell egress from LNs abrogates their trafficking to the affected skin leading to significantly reduced skin inflammation.

Figure 5. γδT17 trafficking induced by GC treatment is dependent on CCR6. (A, B) Ear thickness of WT and Ccr6−/− (a) or CCR2−/− mice (b, n=5) from Day 1 to Day 21. Data are the representative of at least two independent experiments with similar results. Data represent as mean and error. ****P<0.0001 (two-way ANOVA). (c) Summarized neutrophil percentages. Neutrophils were gated on CD45+CD11b+ cells. Data are the representative of at least two independent experiments with similar results (n=3 in each group). *P<0.05 (one-way ANOVA). (d, e) Summarized IL-17 production by skin CD3+, dermal or LNs γδT, Vγ4, Vγ4Vδ4 T cells of WT, Ccr6−/− and Ccr2−/− mice from skin (d), cervical LNs (e, Left) or inguinal LNs (e, Right) on day 21 (n=6 in WT group, n=5 in Ccr6−/−/IMQ/Vas group, n=6 in Ccr6−/−/IMQ/GC group, n=3 in Ccr2−/− group). Data are representative of at least two independent experiments with similar results. ***P<0.001, **P<0.01, *P<0.05 (two-way ANOVA). (f) Ear thickness of WT and Ccr6−/− mice replated with IMQ from Day 35 to Day 42. Data represent as mean and error. ****P<0.0001 (two-way ANOVA). (g) Representative HE stained skin sections from WT or CCR6 KO mice rechallenged with IMQ on day 42. Data in the bar figures are represented as means±SEM.
Figure 6. FTY720 treatment inhibits γδT17 cell trafficking leading to reduced skin inflammation and epidermal thickness. (a) Left. Changes of ear thickness from Day 35 to Day 42 (n=5 in IMQ/Vas, IMQ/GC and IMQ/GC/FTY720 group, n=4 in IMQ/Vas/FTY720 group). Data represent as mean and error. ****P<0.0001 (two-way ANOVA). Right. Summarized neutrophil percentages. Cells were gated on CD45⁺CD11b⁺ cells (n=3 in IMQ group, n=4 in IMQ/FTY720 group). ***P<0.001 (one-way ANOVA). (b-c) Summarized IL-17 production by CD3⁺, dermal or LNs γδT, Vγ4T, Vγ4Vδ4 T cells from skin (b), cervical LNs (c, Left) or inguinal LNs (c, Right) on day 42. Data are representative of at least two independent experiments with similar results (n=3 in IMQ group, n=4 in IMQ/FTY720 group). ****P<0.0001, ***P<0.001, *P<0.05 (two-way ANOVA). Data in the bar figures are represented as means±SEM.
Discussion

In this study, we provide evidence to suggest that dynamic trafficking of pathogenic γδT17 cells plays a critical role in the mechanisms underlying psoriasis recurrence in a mouse model of psoriasis-like dermatitis. Using skin tissues from psoriatic patients during the different disease stages, we discover that many genes and pathways related to psoriasis pathogenesis are associated with different disease statuses. Among these pathways, chemokines/chemokine receptors appear to be a dominant pathway, particularly, CCL20-CCR6 axis. Chemokine CCL20 is considered a potential biomarker for disease severity, systemic inflammation, and vascular endothelial inflammation. Since all T cells express CCR6, it is thus hypothesized that γδ T cells may play a critical role in psoriasis pathogenesis and recurrence. Both innate γδ T cells and adaptive T cells are able to secrete IL-17. Previous studies have shown that γδ T cells are mainly activated and differentiated in the skin and draining LNs. In psoriatic patients, PB γδ T cells are decreased while skin γδ T cells are increased, suggesting potential trafficking of γδ T cells between an inflamed skin and periphery. In the current study, we found the similar γδ T cell trafficking patterns during different disease stages. Skin γδ T cells were increased in untreated lesional skin while decreased upon GC effective treatment. When disease recurred, skin γδ T cells increased again. In contrast, γδ T cells in the PB experienced an opposite wave. Thus, γδ T cell trafficking appears to be correlated with disease progression, resolution, and recurrence. It will be interesting to examine whether decrease of γδ T cell frequency in the PB over time is associated with an increased risk of psoriatic flair.

Although human psoriatic patient studies have established critical correlations between Tγδ and disease development and recurrence, it is difficult to establish the firm causative effect. Previous studies have demonstrated that CD8+ T cell frequency in the PB over time is associated with an increased risk of psoriatic flair. γδT17 cells were increased while they were decreased upon GC effective treatment. Unexpectedly, these innate γδT17 cells were not eliminated as a result of effective GC treatment. In contrast, γδT17 cells were significantly increased in skin draining and distant LNs, suggesting potential redistribution of dermal γδT17 cells. This is reminiscent to the previous study showing Vγ4T17 cells trafficking to distant skin and inducing the secondary IL-17-driven inflammation. More importantly, adoptively transferred γδ T cells from LNs of previously GC-treated mice into naïve mice also induced severe skin inflammation. These data suggest a causative effect of γδ T cells in mediating this phenotype. Interestingly, these GC-treated mice received the second IMQ application on the different site did not phenocopy these effects, reminiscent of human psoriasis recurrence. Our results provide unequivocal evidence that enhanced skin inflammation in previously GC-treated mice is the consequence of dynamic trafficking of γδT17 cells within the skin and skin draining and distant LNs. It is worth noting that although IMQ-induced psoriasis-like dermatitis model has been widely used, this model has its limitations such as unintended consequences of topical treatment. In addition, rechallenge of IMQ on the same skin is different from recurrence in human psoriasis. Future studies are needed to further examine these findings in psoriasis patients during different disease stages.

We demonstrated that CCR6 but not CCR2 is required for γδT17 trafficking. This is in contrast to previous studies showing that CCR2 is expressed on activated γδT17 cells and is essential for their accumulation in inflamed skin. CCR2 is predominantly expressed on monocytes and macrophages and is required for their homing to inflamed skin. Since CCR2 is only expressed on activated γδT17 cells, depletion of CCR2 on them may address the observed discrepancies. Furthermore, a previous study showed that pertussis toxin did not inhibit the migration of γδ T cells from the skin to LNs and sphingosine-1-phosphate receptor 2 (S1PR2) was thought to play a critical role in GC treatment. In contrast, GC effective treatment. Unexpectedly, these γδ T cells that show efficacy to prevent skin inflammation although randomized trials are needed to firmly support their clinical utilization. In this study, we also showed that inhibition of lymphocyte egress by FTY720 abolished γδT17 trafficking leading to reduced skin inflammation. It is thus speculated that use of
CCR6-specific inhibitors or FTY720 during psoriasis remission phase might prevent potential disease recurrence and ameliorate psoriasisiform dermatitis in this mouse model.

One intriguing question is why and how γδT17 cells accumulate in the skin draining and distant LNs upon GC treatment on inflamed skin. We found that the mRNA levels of CCL20 but not CCL2 were increased in the skin draining and distant LNs from GC-treated mice. However, the increased CCL20 mRNA expression was abrogated in CCR6 KO mice (data not shown). A previous study also showed that GC treatment enhanced CCL20 release in bronchial epithelial cells. In summary, our results suggest that dermal γδT17 cells are decreased in the inflamed skin with ameliorated skin inflammation upon GC treatment. These γδT17 cells are not eliminated but accumulated in the draining and distant LNs due to increased CCL20 expression. Accumulation of γδT17 cells in the draining and distant LNs provides a reservoir for their future trafficking back to the skin. Upon re-exposure of the same insults on the same site, pathogenic γδT17 cells can quickly migrate from LNs to the skin leading to a heightened inflammation. This dynamic trafficking between the skin and LNs is CCR6 dependent. Our findings thus provide strong impetus for inhibiting pathogenic γδT17 cells redistribution as an effective treatment to prevent disease relapse in patients with psoriasis and in this psoriasis-like dermatitis mouse model.

Contributors
Conceptualization: JZ, JY and NL. Data curation: NL, HQ, YC, QX, XL, LW, FX, LC, CD, XH. Formal Analysis: DT, ER, JY. Writing — original draft: JY, NL and HQ. Resources: JY and JZ. Writing — review & editing: JY and JZ. All authors have read and approved the final version of the manuscript.

Data sharing statement
RNA-Seq data have been deposited into NCBI GEO with the accession number (GSE114729).

Declaration of interests
ECR received consulting fee from University of South Carolina and Marshall University and participated on a Data Safety Monitoring Board or Advisory Board of National Library of Medicine. All other authors have declared that no conflict of interest exists.

Acknowledgements
The authors are grateful to Drs. Yuping Lai, Jing Wang, Ningli Li, and Honglin Wang for the helpful discussions.

Supplementary materials
Supplementary material associated with this article can be found in the online version at doi:10.1016/j.jebiom.2022.104136.

References
1. Lowes MA, Suarez-Farinas M, Krueger JG. Immunology of psoriasis. Ann Rev Immunol. 2014;32:227–255.
2. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;360(10):971–982.
3. Araujo EG, Finzel S, Engelbrecht M, et al. High incidence of disease recurrence after discontinuation of disease-modifying antirheumatic drug treatment in patients with psoriatic arthritis in remission. Ann Rheum Dis. 2015;74(6):1055–1060.
4. Masson Regnault M, Kostantinou MP, Khemis A, et al. Early relapse of psoriasis after stopping brodalumab: a retrospective cohort study in 77 patients. J Eur Acad Dermatol Venereol. 2017;31(9):1491–1496.
5. Cai Y, Shen X, Ding C, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373(14):1313–1323.
6. Clark RA. Gone but not forgotten: lesional memory in psoriatic skin. J Invest Dermatol. 2011;131(2):285–295.
7. Matos TR, O’Malley JT, Lowy EL, et al. Clinically resolved psoriatic lesions contain psoriasis-specific IL-17-producing alphabeta T cell clones. J Clin Invest. 2017;127(11):4391–4404.
8. Cheuk S, Wilken M, Blomqvist L, et al. Epidermal Th17 and Tc17 cells form a localized disease memory in clinically healed psoriasis. J Immunol. 2014;192(7):3110–3120.
9. Clark RA. Resident memory T cells in human health and disease. Sci Transl Med. 2015;7(29):295pv1.
10. Gallais Serzezel I, Classon C, Cheuk S, et al. Resident T cells in resolved psoriasis steer tissue responses that stratify clinical outcome. J Invest Dermatol. 2018;138(8):1754–1765.
11. Cai Y, Shen X, Ding C, et al. Pivotal role of dermal IL-17-producing gammadelta T cells in skin inflammation. Immunity. 2011;35(4):596–606.
12. Cai Y, Fleming C, Yan J. Dermal gammadelta T cells—a new player in the pathogenesis of psoriasis. Int Immunopharmacol. 2015;16(1):88–91.
13. Mahuchi T, Singh TP, Takekoshi T, et al. γδTCR is required for efferention of psoriasis. J Exp Med. 2011;208(2):333–347.
14. Pantelyushin S, Haak S, Ingold B, et al. Rorγ+ innate lymphocytes and gammadelta T cells initiate psoriasis-like plaque formation in mice. J Clin Invest. 2012;122(5):2452–2466.
15. Hartwig T, Pantelyushin S, Cronford AL, Kulig P, Becher B. Dermal IL-17-producing gammadelta T cells establish long-lived memory in the skin. Eur J Immunol. 2015;45(5):1522–1533.
16. Ramirez-Valle F, Gray EE, Cyster JG. Inflammation induces dermal Vγ9Vδ2+ gammadeltaT cell memory-like cells that travel to distant skin and accelerate secondary IL-17-driven responses. Proc Nat Acad Sci USA. 2015;112(26):8046–8051.
17. Suarez-Farinas M, Fuentes-Duculan J, Lowes MA, Krueger JG. Resolved psoriasis lesions retain expression of a subset of disease-related genes. J Invest Dermatol. 2011;131(2):191–200.
18. van der Fits L, Mourtis S, Voerman JS, et al. Iliquizimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol. 2016;196(8):516–524.
19. Laggner U, Di Meglio P, Perera GK, et al. Identification of a novel proinflammatory human skin-homing Vgamma9Vdelta2 T cell
subset with a potential role in psoriasis. J Immunol. 2011;187(5):2789–2793.

20 Hedrick MN, Lonsdorf AS, Shirakawa AK, et al. CCR6 is required for IL-23-induced psoriasis-like inflammation in mice. J Clin Invest. 2009;119(8):2317–2329.

21 Mabuchi T, Singh TP, Takekoshi T, et al. CCR6 is required for epidermal trafficking of gammadelta-T cells in an IL-24-induced model of psoriasis. J Invest Dermatol. 2013;133(4):164–171.

22 McKenzie DR, Kara EE, Bastow CR, et al. IL-17-producing gammadelta T cells switch migratory patterns between resting and activated states. Nat Commun. 2017;8:1562.

23 Naik S, Bouladoux N, Wilhelm C, et al. Compartmentalized control of skin immunity by resident commensals. Science. 2012;337(6098):1115–1119.

24 Ridaura VK, Bouladoux N, Claesen J, et al. Contextual control of skin immunity and inflammation by Corynebacterium. J Exp Med. 2018;215(7):1471–1480.

25 Cai Y, Xue F, Quan C, et al. A critical role of the IL-1beta-IL-1R signaling pathway in skin inflammation and psoriasis pathogenesis. J Invest Dermatol. 2019;139(5):1146–1156.

26 Chan J, Kihara Y, Jonnalagadda D, Blaho VA. Fingolimod: lessons learned and new opportunities for treating multiple sclerosis and other disorders. Annu Rev Pharmacol Toxicol. 2019;59:149–170.

27 El nabi Y, Abdi S, Al-Abbasi R, et al. Role of CCR6 in psoriasis: a potential biomarker of disease severity, inflammation, and impaired vascular health. J Am Acad Dermatol. 2021;84(4):913–920.

28 Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol. 2017;140(3):645–656.

29 Owczarczuk S, Szczekot W, Krajewska-Wlodarczyk M, Kasprzwicz-Furmanczyk M, Plateck W. Immunological memory of psoriatic lesions. Int J Mol Sci. 2020;21(2):625. https://doi.org/10.3390/ijms21020625.

30 Mashiko S, Edelmayer RM, Bi Y, et al. Persistence of inflammatory phenotype in residual psoriatic plaques in patients on effective biologic therapy. J Invest Dermatol. 2020;140(5):1015–1025.e4.

31 Hawkes JE, Gudjonsson JE, Ward NL. The snowballing literature on imiquimod-induced skin inflammation in mice: a critical appraisal. J Invest Dermatol. 2017;137(4):346–349.

32 Vestergaard C, Just H, Baumgartner Nielsen J, Thostrup-Pedersen K, Deiurman M. Expression of CCR2 on monocytes and macrophages in chronically inflamed skin in atopic dermatitis and psoriasis. Acta Derm Venereol. 2002;82(5):333–338.

33 Willensborg S, Lucas T, van Loo G, et al. CCR2 recruits an inflammatory macrophage subpopulation critical for angiogenesis in tissue repair. Blood. 2012;119(3):617–625.

34 Nakamizo S, Egawa G, Tomura M, et al. Dermal Vgamma4(+) gammadelta T cells possess a migratory potency to the draining lymph nodes and modulate CD8(+) T-cell activity through TNF-alpha production. J Invest Dermatol. 2015;135(4):1007–1015.

35 Laidlaw BJ, Gray EE, Zhang Y, Ramirez-Valle F, Cyster JG. Sphingosine-1-phosphate receptor 2 restrains egress of gammadelta T cells from the skin. J Exp Med. 2019;216(7):1497–1506.

36 Zijlstra GJ, Fattahi F, Rozeveld D, et al. Glucocorticoids induce the production of the chemoattractant CCL20 in airway epithelium. Eur Respir J. 2014;44(2):561–570.

37 Flemming C, Cai Y, Sun X, et al. Microbiota-activated CD103(+) DCs stemming from microbiota adaptation specifically drive gammadelta T17 proliferation and activation. Microbiome. 2017;5(1):46. https://doi.org/10.1186/s40168-017-0263-9.